Strategies Adopted by Innovator Companies in Response to Biosimilars Competition
By Charu Manaktala, MD, MBBS, Raymond A. Huml, MS, DVM, RAC, Nigel Rulewski, MD -
Published 10 April 2017
This article examines key strategies being adopted by the innovator companies and discusses the impact these strategies are likely to have on the future market for biosimilars.
Categories: Features, Europe, US, EMA, FDA, Biologics and biotechnology, Government affairs, Regulatory strategy, Submission and registration
Tags: Biosimilars, Intellectual Property, Litigation, Patent Extension